Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Views - The company reported a significant year-on-year revenue growth of 32.1% in Q1 2025, achieving a total revenue of 2 billion yuan. However, there was a quarter-on-quarter decline of 8.1% [2][6]. - The net profit attributable to shareholders reached 230 million yuan, reflecting a year-on-year increase of 39.3% and a quarter-on-quarter decrease of 4.5% [2][6]. - The company’s organic fluorine chemical products are expected to continue their high growth trajectory, driven by stable demand for fluorinated pharmaceutical intermediates, cleaning agents, cooling fluids, and modified copolymers [7][13]. - The company is expanding its production capacity overseas, with plans to invest up to 26 million USD in a new electronic chemical production base in Malaysia to meet the growing demand in the Southeast Asian market [13]. Summary by Sections Financial Performance - In Q1 2025, the company achieved a gross profit margin of 24.6%, down 2.7 percentage points year-on-year and 0.4 percentage points quarter-on-quarter. The net profit margin was 11.6%, up 0.8 percentage points year-on-year and 0.3 percentage points quarter-on-quarter [7][12]. - The company expects a decline in revenue and profit margins primarily due to the pressure on electrolyte sales and market conditions [7]. Product Development and Market Position - The company is implementing a "production generation + research generation + reserve generation" strategy to enhance its product offerings. The first-generation products maintain stable market share, while second-generation products are experiencing strong demand and rapid sales growth [7][13]. - The global electronic fluorinated liquid market is currently in a supply transition phase, providing growth opportunities for the company's fluorinated liquids [7][13]. Future Outlook - The company forecasts net profits attributable to shareholders of 1.2 billion yuan, 1.46 billion yuan, and 1.86 billion yuan for the years 2025, 2026, and 2027, respectively [13].